Announced Sat, 18 Jul · 16:56 IST
Rossari Biotech Q1 FY27 results up, ESOP grant and subsidiary transfer approved
General View source PDF
ROSSARI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-3.4%1-day move
₹530.05
prior close
—
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————-3.4-6.2-7.2-7.6-1.5—————
Up moveDown movePending
AI summary
Rossari Biotech posted strong Q1 FY27 results. Consolidated revenue rose to Rs 697.2 cr from Rs 543.7 cr YoY, with PAT at Rs 35.1 cr versus Rs 33.6 cr. Standalone revenue was Rs 482.3 cr, up from Rs 365.8 cr. Board also granted 4,000 ESOP options at Rs 531 each, allotted 2,500 shares under ESOP 2019, and approved transfer of its Saudi subsidiary RILC to Rossari Singapore for about Rs 24 cr as internal restructuring.
Likely market impact
Strong top-line growth and steady profitability. ESOP grants and intra-group subsidiary transfer are routine with no material financial impact.